- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05423847
Triage UltraSound in Tb Endemic Regions (TrUST)
Point-of-care Ultrasound for the Diagnosis and Risk Stratification of Lower Respiratory Tract Infections in TB Endemic Regions: a Multicenter Prospective Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Design International multicentre prospective cohort study
Setting This study aims to explore the performance of POCUS in a pre-hospital setting in countries with different prevalences of HIV: South- Africa (high prevalence), Benin (low prevalence) and Mali (low prevalence).
Study procedures Pre-recruitment training Before initiating the study, participating clinicians will benefit from lung ultrasound (LUS) and POCUS protocols for extra pulmonary TB (FASH+ exam) training with a field expert. The participating clinicians are required to pass a final expert test before start of patient recruitment and to have a minimum of 20 supervised US.
Inclusion (Day 0) Patients inclusion will be performed over a period of 18 to maximum 24 months. Recruitment will stop before the anticipated end if the inclusion of 1000 patients is reached.
Clinical data Data collected include demographic characteristics (age, sex, occupation etc.), past medical history (previous TB, Coronavirus Disease (COVID), vaccination status, documented past episodes of COVID-19, HIV status,…), symptoms (respiratory symptoms, specific COVID-19 symptoms (from the Centers for Disease Control COVID checklist), specific pulmonary TB symptoms (from the CDC TB checklist) and routine clinical examination findings (vital parameters, oxygen saturation, lung auscultation,…).
Laboratory analyses
Analyses performed on site:
- HIV screening with a serial two rapid test algorithm as per World Health Organization (WHO) guidelines : Screening with Alere Determine combo®; if positive, confirmation by a second rapid test First Response® HIV 1-2-0, CD4 count and/or Viral load as per national guidelines.
- Sputum for GeneXpert Mycobacterium Tuberculosis (MTB)/rifampicine (RIF) assay
- Induced sputum for a new GeneXpert MTB assay if a routine spot and second morning GeneXpert MTB is negative and sputum quality was low (salivary) as per WHO consolidated guidelines
- Sputum for Gram stain and standard bacteriological culture
- Nasopharyngeal swab for Severe Acute Respiratory Syndrome Coronovirus (SARS-CoV-2) real-time polymerase chain reaction (RT-PCR) (Cepheid Xpert Xpress SARS-CoV-2) Since the additional diagnostic yield of mycobacterial culture is shown to be very low in adult patients with cough in Benin, it is reserved for GenXpert MTB/RIF resistant cases, specimens other than sputum (e.g. pleural effusions, where sensitivity of GeneXpert MTB/RIF is low) and patients with treatment failure. Mycobacterial culture will be done on solid medium (Löwenstein-Jensen).
Analyses performed retrospectively on stored samples:
- Nasopharyngeal swab: PCR for influenza
- Sputum: syndromic molecular panel targeting influenza and atypical bacteria. Radiological examinations
- Chest X-Ray (CXR) - face: digital format will be stored
- LUS exam using a standard point-of-care ultrasound device (ultrasound-on-a-chip), LUS will be recorded according to a standard 12-point acquisition protocol with 4 additional apical sites (2 subclavicular and 2 axillary) for improved TB detection.
- This involves scanning both apexes, the anterior and posterior apexes, anterior superior, anterior inferior, posterior superior, posterior inferior and lateral thorax regions
- FASH plus exam using a standard point-of-care ultrasound device. The FASH plus protocol will be performed in a standardized manner as previously described.
All US images captured will be digitally recorded and transferred via a secured internet connection along with relevant metadata to a secure server for storage. For study quality control purposes, the quality of the image and the interpretation of a random sample of images will be evaluated retrospectively by an experienced radiologist.
Clinician-evaluated LUS and FASH All LUS and FASH exams will be read by 2 independent readers blinded to patients diagnosis and outcome. A third reader will solve discrepancies between the two readers. They will fill in a standardized LUS and FASH report.
AI-evaluated LUS and FASH The US images will be further used for secondary studies developing deep learning algorithms for LUS and FASH diagnosis.
Follow-up (D7 and D28) Patients will receive a follow-up phone call by the study nurse on day 7 and day 28. Data on the clinical evolution are collected: hospitalization, non-invasive ventilation, intubation, death.
Follow-up of TB treatment failures and deaths until D180 TB patients will be followed in the national TB register and treatment failures will be recorded at 6 months of treatment (according to national guidelines).
Deaths will be recorded until D180 as well.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Noémie Boillat-Blanco, MD-PhD, PD
- Phone Number: +41 (0)79 556 16 86
- Email: noemie.boillat@chuv.ch
Study Contact Backup
- Name: Veronique Suttels, MD
- Phone Number: +229 97 44 87 82
- Email: veronique.suttels@outlook.com
Study Locations
-
-
Atlantic
-
Cotonou, Atlantic, Benin
- Recruiting
- CNHUPPC
-
Contact:
- Gildas Agodokpessi, Prof
- Email: aggildas@yahoo.fr
-
-
-
-
-
Bamako, Mali
- Not yet recruiting
- CHU point G
-
Contact:
- Khadidia Ouattara, MD
- Email: zankhadi@gmail.com
-
-
-
-
-
Acornhoek, South Africa
- Recruiting
- Wits Rural University
-
Contact:
- Jacques Du Toit
- Email: jacques.dutoit1@wits.ac.za
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Benin: 6'500 cumulative total detected and declared COVID-19 cases since march 2020 to date (NB true COVID-19 incidence unknown due to undertesting), TB incidence 55/100'000/year, low HIV (prevalence < 2%)
- South Africa: 1,522'697 cumulative total detected and declared COVID-19 cases since march 2020 to date TB incidence 615/100.000/year, high HIV (prevalence approximately 20%)
- Mali: 30'420 cumulative total detected and declared COVID-19 cases since march 2020 to date (NB true COVID-19 incidence unknown due to undertesting), TB incidence 52/100'000/year, low HIV (prevalence < 2%)
Description
Inclusion Criteria:
- Age ≥18 years
- Suspicion of lower respiratory tract infection (defined as presence of cough with at least one of the following: fever, dyspnea/tachypnea, sputum production, chest pain, hemoptysis or cachexia)
Exclusion Criteria:
- Cough/dyspnea from a definite non-infectious origin (cardiac, asthmatic...)
- Inability to cooperate with ultrasound procedure
- Inability to sign informed consent (third witness procedure available for illiterate patients)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Benin1
Benin urban recruitment site National teaching hospital for tuberculosis, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
Mali1
Mali urban recruitment site University Hospital Bamako, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
South-Africa1
South-Africa rural recruitment site 1 Tintswalo hospital, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
South-Africa2
South-Africa rural recruitment site 2 Zithulele hospital, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of LUS for the detection of TB
Time Frame: 18 to 24 months
|
For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax).
Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards
|
18 to 24 months
|
Specificity of LUS for the detection of TB
Time Frame: 18 to 24 months
|
For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax).
Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards
|
18 to 24 months
|
Sensitivity of FASH PLUS for the detection of TB
Time Frame: 24 to 36 months
|
For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites).
Sensitivity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Specificity of FASH PLUS for the detection of TB
Time Frame: 24 to 36 months
|
For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites).
Specificity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Sensitivity of combined LUS and FASH PLUS features for the detection of TB
Time Frame: 24 to 36 months
|
Sensitivity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Specificity of combined LUS and FASH PLUS features for the detection of TB
Time Frame: 24 to 36 months
|
Specificity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Sensitivity of AI-interpreted LUS for the detection of TB
Time Frame: 24 to 36 months
|
LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Sensitivity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Specificity of AI-interpreted LUS for the detection of TB
Time Frame: 24 to 36 months
|
LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Specificity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Sensitivity of AI-interpreted FASH PLUS for the detection of TB
Time Frame: 24 to 36 months
|
FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Sensitivity of FASH PLUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Specificity of AI-interpreted FASH PLUS for the detection of TB
Time Frame: 24 to 36 months
|
FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Specificity of FASH PLUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS
Time Frame: 12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS to assess its feasibility, sustainability and acceptability
|
12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support
Time Frame: 12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support to assess its feasibility, sustainability and acceptability
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mary-Anne Hartley, MD-PhD, Ecole Polytechnique Fédérale de Lausanne
- Principal Investigator: Noémie Boillat Blanco, MD-PhD, Lausanne University Hospital
- Principal Investigator: Veronique Suttels, MD, Lausanne University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CGRB11362
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
Hu YinanEnrolling by invitationSialic Acid | Superoxide Dismutase | Lipid PneumoniaChina
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
Clinical Trials on POCUS
-
Youngstown State UniversityRecruitingPatellofemoral DisorderUnited States
-
Randa Ahmed SarhanNot yet recruitingDyspnea | Chronic Renal Failure
-
Alexandria UniversityNot yet recruiting
-
St. Justine's HospitalCompletedChildren | UrinalysisCanada
-
Sheba Medical CenterRecruitingCardiovascular Diseases | Valvular Heart DiseaseIsrael
-
Cliniques universitaires Saint-Luc- Université...Grand Hôpital de Charleroi; Université de Liège; Clinique Saint-Jean, Bruxelles; Clinique Saint Pierre OttigniesNot yet recruiting
-
FlevoziekenhuisRecruitingVolume StatusNetherlands
-
University of MinnesotaCompletedCoronavirus Infection | Covid-19 | COVID | SARS-CoV-2United States
-
Eckehart SCHÖLLBasel Academy for Quality and Research in Medicine; Prof. Dr. Werner Vach... and other collaboratorsRecruitingElbow Fracture | Elbow Sprain | Distal Humerus Fracture | Radial Head Fracture | Coronoid Process FractureSwitzerland
-
Chinese University of Hong KongGormin Tan gtanEnrolling by invitation